SDZ285-428 is primarily used in research settings as a selective antagonist for serotonin receptors, particularly the 5-HT2B subtype. Its main application lies in studying cardiovascular function and valvular heart disease, as activation of 5-HT2B receptors has been linked to heart valve proliferation. By blocking this receptor, SDZ285-428 helps investigate the role of serotonin signaling in cardiac pathologies. It is also utilized in neuroscience research to dissect serotonin’s involvement in mood regulation, drug-induced cardiotoxicity, and behavioral models. Due to its selectivity, it serves as a valuable tool compound in pharmacological assays and in vivo studies aiming to clarify receptor-specific effects without significant off-target activity.